| Community Health Centers Of Burlington Inc | |
|
617 Riverside Ave Burlington VT 05401-1601 | |
| (802) 264-8159 | |
| (802) 860-4325 |
| Full Name | Community Health Centers Of Burlington Inc |
|---|---|
| Speciality | Family Medicine |
| Location | 617 Riverside Ave, Burlington, Vermont |
| Authorized Official Name and Position | Kate Reed (INTERIM CHIEF EXECUTIVE OFFICER) |
| Authorized Official Contact | 8022648190 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Community Health Centers Of Burlington Inc 617 Riverside Ave Burlington VT 05401-1601 Ph: (802) 264-8159 | Community Health Centers Of Burlington Inc 617 Riverside Ave Burlington VT 05401-1601 Ph: (802) 264-8159 |
| NPI Number | 1689678963 |
|---|---|
| Provider Enumeration Date | 06/02/2005 |
| Last Update Date | 02/24/2020 |
| Medicare PECOS PAC ID | 2062491251 |
|---|---|
| Medicare Enrollment ID | O20040720000792 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1689678963 | NPI | - | NPPES |
| VT4600 | Other | VT | VERMONT MANAGED CARE |
| 8000704 | Other | VT | LADIES FIRST |
| 4600 | Medicaid | VT | |
| VT4600 | Other | VT | BLUE CROSS BLUE SHIELD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 24908 (Vermont) | Primary |
| Provider Name | Stephen C Baad |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1629027271 PECOS PAC ID: 8224017405 Enrollment ID: I20040720000713 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Wayne Leslie Warnken |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1326024878 PECOS PAC ID: 9537123773 Enrollment ID: I20041117000158 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Naya Pyskacek |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1497710560 PECOS PAC ID: 3779549076 Enrollment ID: I20041208000743 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | John R Brooklyn |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1588640635 PECOS PAC ID: 5193775419 Enrollment ID: I20050125000529 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Rachel H Inker |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1558347096 PECOS PAC ID: 4789634007 Enrollment ID: I20050125000559 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Douglas C Bugbee |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1942308028 PECOS PAC ID: 8628021128 Enrollment ID: I20050224000504 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Clodagh A Coghlan |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1417908286 PECOS PAC ID: 7618912148 Enrollment ID: I20050624000101 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Jennifer S Laurent |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1598735128 PECOS PAC ID: 8123063658 Enrollment ID: I20050624000131 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Richard B White |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1467448621 PECOS PAC ID: 5991730632 Enrollment ID: I20050930000213 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Betsy A Fowler |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1669438131 PECOS PAC ID: 1850311184 Enrollment ID: I20051201000740 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Ann Goering |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1790810489 PECOS PAC ID: 5496732091 Enrollment ID: I20060329000466 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Adam W Kunin |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1306813159 PECOS PAC ID: 6800805003 Enrollment ID: I20060417000699 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Christine D Northrup |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1821161183 PECOS PAC ID: 0244249464 Enrollment ID: I20060418000049 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Beach Conger |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1023006921 PECOS PAC ID: 6305810789 Enrollment ID: I20060727000236 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Tara M Chasnoff |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1730237074 PECOS PAC ID: 7911001029 Enrollment ID: I20070329000518 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Vivian R Esparza |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1982658654 PECOS PAC ID: 3870699846 Enrollment ID: I20070508000485 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Anne M Knott |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1164596730 PECOS PAC ID: 0446342067 Enrollment ID: I20070827000572 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Karen E Sokol |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1467666180 PECOS PAC ID: 4486741113 Enrollment ID: I20071029000105 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Mark A Pitcher |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1285682666 PECOS PAC ID: 7911986278 Enrollment ID: I20080325000398 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Peter Gunther |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1851341671 PECOS PAC ID: 2466431721 Enrollment ID: I20080325000418 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Harris Kiva Strokoff |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1497866701 PECOS PAC ID: 0840354619 Enrollment ID: I20090123000306 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Annika Hawkins-hilke |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1538398474 PECOS PAC ID: 6507911716 Enrollment ID: I20090910000633 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Jena S Katzman |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1215254289 PECOS PAC ID: 1052503398 Enrollment ID: I20101005001172 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Leighton F Johnson |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1427350206 PECOS PAC ID: 2062691108 Enrollment ID: I20110121000636 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Diana J Clayton |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1790075869 PECOS PAC ID: 9234317108 Enrollment ID: I20110623000240 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Heather Stein |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1073786778 PECOS PAC ID: 7315116068 Enrollment ID: I20110815000152 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Jennifer Evansfirst |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1679855977 PECOS PAC ID: 4688848963 Enrollment ID: I20111123000143 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Jun Fu |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1538461066 PECOS PAC ID: 1850568890 Enrollment ID: I20120117000019 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Gopichand Vallabhaneni |
|---|---|
| Provider Type | Practitioner - Oral Surgery |
| Provider Identifiers | NPI Number: 1376638536 PECOS PAC ID: 4688827843 Enrollment ID: I20130122000149 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Anna Leavey |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1437405958 PECOS PAC ID: 6204074347 Enrollment ID: I20130530000519 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Paulette J Thabault |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1366756686 PECOS PAC ID: 8325289853 Enrollment ID: I20130726000046 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Megan O Brien |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1033421110 PECOS PAC ID: 5092909465 Enrollment ID: I20130813000581 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Christianna Pilsucki |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1831371996 PECOS PAC ID: 8527200666 Enrollment ID: I20130820000335 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Amy Mcgettrick |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1427372234 PECOS PAC ID: 7517192065 Enrollment ID: I20131108001421 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Sarah R Morse |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1164857694 PECOS PAC ID: 1759517311 Enrollment ID: I20131204000861 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Stephanie Parent |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1811000375 PECOS PAC ID: 9133352487 Enrollment ID: I20140512002070 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Courtney A Walker-borch |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1457767410 PECOS PAC ID: 2163649682 Enrollment ID: I20140807000122 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Jessica S Schwartz |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1376943431 PECOS PAC ID: 0143543033 Enrollment ID: I20141230000197 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Kara Fauth |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1669622064 PECOS PAC ID: 4688991201 Enrollment ID: I20150319001637 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Leo Isaac Kline |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1487049672 PECOS PAC ID: 9739400151 Enrollment ID: I20150610000785 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Adam Russell Greenlee |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1013238229 PECOS PAC ID: 2961718689 Enrollment ID: I20150826000895 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Lincoln Heath |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1811253800 PECOS PAC ID: 2264748904 Enrollment ID: I20150826001583 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Elisabeth B. Wells |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1972985745 PECOS PAC ID: 4183934615 Enrollment ID: I20151112000664 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Theresa L Hetzler |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1619978293 PECOS PAC ID: 6305989930 Enrollment ID: I20151214000877 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Tamara Orear |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1497114607 PECOS PAC ID: 9234436288 Enrollment ID: I20160318001282 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Michelle Dianne Dorwart |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1598007486 PECOS PAC ID: 0941500367 Enrollment ID: I20160830000287 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Philippa Owens |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1598047193 PECOS PAC ID: 2365722196 Enrollment ID: I20161213000557 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Kristen Gray |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1346796463 PECOS PAC ID: 2860773074 Enrollment ID: I20161230001053 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Zachary Schwartz |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1912446097 PECOS PAC ID: 6709161375 Enrollment ID: I20170322000362 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Irene Koplinka-loehr |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1407275126 PECOS PAC ID: 2769754803 Enrollment ID: I20170823004323 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Blake C Mcknight |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1497275804 PECOS PAC ID: 1355614256 Enrollment ID: I20170828004040 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Lindsay C Arzberger |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1023542693 PECOS PAC ID: 7911270210 Enrollment ID: I20170908000725 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Samuel Weiss |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1093225831 PECOS PAC ID: 1254607385 Enrollment ID: I20171018000040 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Margaret Spottswood |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1144529611 PECOS PAC ID: 3971806043 Enrollment ID: I20180111002574 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Jessica A Griffin |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1518328749 PECOS PAC ID: 9335408624 Enrollment ID: I20180112000062 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Karla Martinez-dulmer |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1912267964 PECOS PAC ID: 5496056616 Enrollment ID: I20180206000633 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Casey Lynn Smith-speirs |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1316330434 PECOS PAC ID: 7517287162 Enrollment ID: I20180307000591 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Matthew Perret |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1003329335 PECOS PAC ID: 2365703212 Enrollment ID: I20180309001857 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Grace Zimmer |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1487148094 PECOS PAC ID: 8729330519 Enrollment ID: I20181005000083 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Mary Anne Kohn |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1639521412 PECOS PAC ID: 4082901186 Enrollment ID: I20181106002409 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Megan E Mogerley |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1639649205 PECOS PAC ID: 2769728088 Enrollment ID: I20190108001375 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Meaghan Mcfadden |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1558828111 PECOS PAC ID: 1254671266 Enrollment ID: I20190328001323 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Rochelle A Paquette |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1730567629 PECOS PAC ID: 3870868961 Enrollment ID: I20190510001266 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Jacob Shaw |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1023497344 PECOS PAC ID: 7911213921 Enrollment ID: I20190712000350 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Krysten Farrell |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1457983611 PECOS PAC ID: 5597193763 Enrollment ID: I20200323000396 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Christopher T Vogt |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1336404722 PECOS PAC ID: 3375762024 Enrollment ID: I20200520002524 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Samuel Lurie |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1295279628 PECOS PAC ID: 4688085384 Enrollment ID: I20201202000789 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Lauren Carpenter |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1013317908 PECOS PAC ID: 3072928258 Enrollment ID: I20210222000708 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Emily-anne Sanders Garcia |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1588295315 PECOS PAC ID: 2668889627 Enrollment ID: I20210318002713 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Stephanie Szkaradnik |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1992336234 PECOS PAC ID: 6305253105 Enrollment ID: I20210323001431 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Margaret Graham |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1477057834 PECOS PAC ID: 6901160589 Enrollment ID: I20210806002872 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Adrienne R Jarvis |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1629573282 PECOS PAC ID: 5698039220 Enrollment ID: I20210823002063 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Lisa Louise Hardy |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1831767672 PECOS PAC ID: 3072919257 Enrollment ID: I20210914001710 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Michael F Ialeggio |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1770070724 PECOS PAC ID: 5799183273 Enrollment ID: I20211014000122 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Colin Hunt |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1447783790 PECOS PAC ID: 6002205374 Enrollment ID: I20211109000663 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Tyler Patrick O'bryan |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1750867768 PECOS PAC ID: 2163812728 Enrollment ID: I20211214001963 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Julia M Zdanowicz |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1841960382 PECOS PAC ID: 0042606212 Enrollment ID: I20220415001126 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Meagan Rohde |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1164955753 PECOS PAC ID: 3375924178 Enrollment ID: I20220725001759 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Emma Leonard |
|---|---|
| Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
| Provider Identifiers | NPI Number: 1619616919 PECOS PAC ID: 9739560541 Enrollment ID: I20220725002120 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Elizabeth D Nowalk |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1407418478 PECOS PAC ID: 7719215045 Enrollment ID: I20220817003425 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Sara Clafferty Headley |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1265858245 PECOS PAC ID: 4082097134 Enrollment ID: I20220823000438 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Varney Glassman |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1477179661 PECOS PAC ID: 5597140392 Enrollment ID: I20220914003688 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Kayla Mae Green |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1033840970 PECOS PAC ID: 5294110748 Enrollment ID: I20220920000072 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Alyssa Basiliere |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1326767112 PECOS PAC ID: 0042696882 Enrollment ID: I20221003001771 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Shannon Lucy |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1376262519 PECOS PAC ID: 7719353663 Enrollment ID: I20221018000072 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Sarah Arvidson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1528682937 PECOS PAC ID: 1254744766 Enrollment ID: I20221103003098 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Catherine Benoit |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1962120568 PECOS PAC ID: 5092185645 Enrollment ID: I20221223000939 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Kevin John Sheasgreen |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1508450677 PECOS PAC ID: 2567871916 Enrollment ID: I20230608000966 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Caitlyn Patricia Tengwall |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1508410119 PECOS PAC ID: 0345608675 Enrollment ID: I20230628003924 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Maria Delia Crosby |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1013513217 PECOS PAC ID: 6507271004 Enrollment ID: I20230823000387 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Natalie Leah Antosh |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1437778685 PECOS PAC ID: 8527489061 Enrollment ID: I20230907000273 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Katherine Elizabeth Logan |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1750905006 PECOS PAC ID: 5991123705 Enrollment ID: I20231010000066 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Jacqueline Cahill |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1225634108 PECOS PAC ID: 7517314073 Enrollment ID: I20231106002639 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Jamie L Charlson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1417630294 PECOS PAC ID: 0941659320 Enrollment ID: I20231211001783 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
| Provider Name | Sarah Booz |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1841072436 PECOS PAC ID: 6608211982 Enrollment ID: I20240226003779 |
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
News Archive
The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.
An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.
Guang Yue, PhD, of Kessler Foundation has been awarded an NIH grant for$1,962,767 to study the impact of high-effort training on the muscle weakness that impairs quality life among many individuals with cancer.
› Verified 7 days ago
University Of Vermont Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 425 Pearl St, Burlington, VT 05401 Phone: 802-656-3350 Fax: 802-656-8178 | |
Chcb Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 617 Riverside Ave, Burlington, VT 05401 Phone: 802-864-6309 Fax: 802-860-4325 | |
Affiliates In Obstetrical & Gynecological Care Inc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 96 Colchester Ave, Burlington, VT 05401 Phone: 802-658-0505 | |
Ameriwound Physicians Inc Vt Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 98 Starr Farm Rd, Burlington, VT 05408 Phone: 802-658-6717 | |
Sandra Nigolian Msw Psychotherapy Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 431 Pine St # G13, Burlington, VT 05401 Phone: 802-338-5122 | |
Helios Natural Medicine Pllc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 13 Kilburn St, Burlington, VT 05401 Phone: 802-540-0066 | |
State Of Vermont Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 108 Cherry St, Burlington, VT 05401 Phone: 802-863-7338 Fax: 802-863-7635 |